These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
560 related articles for article (PubMed ID: 6458884)
21. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. Hansen CR; Pressler T; Høiby N J Cyst Fibros; 2008 Nov; 7(6):523-30. PubMed ID: 18693078 [TBL] [Abstract][Full Text] [Related]
22. Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution. Sawicki GS; Signorovitch JE; Zhang J; Latremouille-Viau D; von Wartburg M; Wu EQ; Shi L Pediatr Pulmonol; 2012 Jan; 47(1):44-52. PubMed ID: 21815282 [TBL] [Abstract][Full Text] [Related]
23. In vitro interactions of tobramycin with various nonantibiotics against Pseudomonas aeruginosa and Burkholderia cenocepacia. Treerat P; Widmer F; Middleton PG; Iredell J; George AM FEMS Microbiol Lett; 2008 Aug; 285(1):40-50. PubMed ID: 18513356 [TBL] [Abstract][Full Text] [Related]
24. Variable antibiotic susceptibility in populations of Pseudomonas aeruginosa infecting patients with bronchiectasis. Gillham MI; Sundaram S; Laughton CR; Haworth CS; Bilton D; Foweraker JE J Antimicrob Chemother; 2009 Apr; 63(4):728-32. PubMed ID: 19193658 [TBL] [Abstract][Full Text] [Related]
25. Diagnostic value of serum antibodies in early Pseudomonas aeruginosa infection in cystic fibrosis patients. Ratjen F; Walter H; Haug M; Meisner C; Grasemann H; Döring G Pediatr Pulmonol; 2007 Mar; 42(3):249-55. PubMed ID: 17243185 [TBL] [Abstract][Full Text] [Related]
26. Azlocillin compared with carbenicillin in the treatment of bronchopulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis. Penketh A; Hodson ME; Gaya H; Batten JC Thorax; 1984 Apr; 39(4):299-304. PubMed ID: 6426075 [TBL] [Abstract][Full Text] [Related]
27. Controlled trial of cycled antibiotic prophylaxis to prevent initial Pseudomonas aeruginosa infection in children with cystic fibrosis. Tramper-Stranders GA; Wolfs TF; van Haren Noman S; van Aalderen WM; Nagelkerke AF; Nuijsink M; Kimpen JL; van der Ent CK Thorax; 2010 Oct; 65(10):915-20. PubMed ID: 20729233 [TBL] [Abstract][Full Text] [Related]
28. Clinical impact of reducing routine susceptibility testing in chronic Pseudomonas aeruginosa infections in cystic fibrosis. Etherington C; Hall M; Conway S; Peckham D; Denton M J Antimicrob Chemother; 2008 Feb; 61(2):425-7. PubMed ID: 18156280 [TBL] [Abstract][Full Text] [Related]
29. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. Burns JL; Van Dalfsen JM; Shawar RM; Otto KL; Garber RL; Quan JM; Montgomery AB; Albers GM; Ramsey BW; Smith AL J Infect Dis; 1999 May; 179(5):1190-6. PubMed ID: 10191222 [TBL] [Abstract][Full Text] [Related]
30. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response. Ciofu O APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154 [TBL] [Abstract][Full Text] [Related]
31. [Bacteriological monitoring of the treatment of Pseudomonas aeruginosa infections with amikacin administrated at once-daily dosis in patients with cystic fibrosis]. Canis F; Husson MO; Vic P; Ategbo S; Turck D; Courcol R; Leclerc H Pathol Biol (Paris); 1995 Apr; 43(4):343-51. PubMed ID: 7567127 [TBL] [Abstract][Full Text] [Related]
32. Azlocillin and gentamicin in respiratory tract infections with Pseudomonas aeruginosa in patients with cystic fibrosis. Malmborg AS; Alfredsson H; Kusoffsky E; Strandvik B Scand J Infect Dis Suppl; 1981; 29():64-9. PubMed ID: 6947407 [TBL] [Abstract][Full Text] [Related]
33. Effect of oxygen limitation on the in vitro activity of levofloxacin and other antibiotics administered by the aerosol route against Pseudomonas aeruginosa from cystic fibrosis patients. King P; Citron DM; Griffith DC; Lomovskaya O; Dudley MN Diagn Microbiol Infect Dis; 2010 Feb; 66(2):181-6. PubMed ID: 19828274 [TBL] [Abstract][Full Text] [Related]
34. Alternative antibiotics for the treatment of Pseudomonas infections in cystic fibrosis. Mastella G; Agostini M; Barlocco G; Bonomi U; Borgo G; Bozzino L; Cabrini G; Cappelletti LM; Castellani L; Conforti M J Antimicrob Chemother; 1983 Jul; 12 Suppl A():297-311. PubMed ID: 6311788 [TBL] [Abstract][Full Text] [Related]
35. Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis. Stanojevic S; Waters V; Mathew JL; Taylor L; Ratjen F J Cyst Fibros; 2014 Mar; 13(2):172-8. PubMed ID: 24091166 [TBL] [Abstract][Full Text] [Related]
36. Pharmacodynamics of tobramycin in patients with cystic fibrosis. Mouton JW; Jacobs N; Tiddens H; Horrevorts AM Diagn Microbiol Infect Dis; 2005 Jun; 52(2):123-7. PubMed ID: 15964500 [TBL] [Abstract][Full Text] [Related]
37. Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions. McCaughey G; McKevitt M; Elborn JS; Tunney MM J Cyst Fibros; 2012 May; 11(3):163-72. PubMed ID: 22138067 [TBL] [Abstract][Full Text] [Related]
38. Azlocillin in respiratory tract infections with Pseudomonas aeruginosa in children with cystic fibrosis. Michalsen H; Bergan T Chemotherapy; 1980; 26(2):135-40. PubMed ID: 7363708 [TBL] [Abstract][Full Text] [Related]
39. Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study. Hansen CR; Pressler T; Koch C; Høiby N J Cyst Fibros; 2005 Mar; 4(1):35-40. PubMed ID: 15752679 [TBL] [Abstract][Full Text] [Related]